More than 1,000 booths showcase next-generation printing, packaging and signage solutions from Malaysian and international companies

KUALA LUMPUR, Malaysia, Aug. 12, 2026 /PRNewswire/ — The 16th International Printing, Paper, Packaging Machinery Exhibition (IPMEX Malaysia 2026) officially opened today at the Malaysia International Trade and Exhibition Centre (MITEC), officiated by YB Datuk Seri Dr. Wee Ka Siong, Member of Parliament for Ayer Hitam and President of the Malaysian Chinese Association (MCA). The four-day exhibition brings the printing, packaging, labelling, signage and textile-printing industries together around automation, sustainability and new commercial opportunities.

Organised by Kaizer Exhibitions & Conferences Sdn Bhd under the theme “Print Package Possibility”, IPMEX Malaysia 2026 runs from 12 to 15 August 2026. The exhibition is endorsed by the Malaysia External Trade Development Corporation (MATRADE), supported by the Malaysia Convention & Exhibition Bureau (MyCEB) and 15 industry associations.

Malaysia’s printing, packaging, signage and textile industries are essential to our commercial and export ecosystem. We must support SMEs in adopting practical automation, AI-driven inspection, energy-efficient equipment and more sustainable materials, while continuing to upskill our workforce. Platforms such as IPMEX and Sign Malaysia connect local businesses with global technology and partnerships, helping them raise productivity, meet international standards and strengthen Malaysia’s competitiveness in regional supply chains,” said YB Datuk Seri Ir. Dr. Wee Ka Siong.

Occupying 12,530 square metres, the 16th edition features 214 exhibiting companies, comprising 90 international companies and 124 Malaysian companies. Participants represent China, Italy, South Korea, Singapore, the United States and Malaysia, while the organiser expects 13,389 trade visitors across the four days. The scale reflects IPMEX’s continued development as a regional sourcing and technology platform for printers, converters, brand owners, sign makers, equipment distributors and buyers.

“IPMEX Malaysia 2026 is designed to move beyond a static machinery showcase. By bringing commercial printing, smart packaging, label production and visual signage into one sourcing environment, we aim to help regional businesses adopt automation, AI-enabled inspection, digital workflows and lower-waste production,” said Ms. Belle Yam, Managing Director of Kaizer Exhibitions & Conferences Sdn Bhd.

IPMEX Malaysia 2026 is co-located with Sign Malaysia Exhibition, themed “LED Light Up the City”, and features zones for Label & Flexible Packaging and Textile Print. Together, the platforms connect industrial print, paper and packaging machinery with signage, digital displays, advertising media and print applications. This integrated format enables visitors to source across the value chain, from raw print media and automated finishing systems to packaging, labels and illuminated signage.

Technology highlights include high-speed digital and variable-data printing, smart label production, flexible and corrugated packaging, pre-press and post-press systems, UV-LED printing, direct-to-garment and direct-to-film solutions, automated visual inspection, interactive displays and more sustainable inks and materials. Featured brands and technology providers include Epson, HP, Mimaki, Konica Minolta, Ricoh, Kodak, Mutoh, Pulisi and Malaysian manufacturer STH Wire.

Business-matching, live demonstrations and networking programmes will run throughout the exhibition, helping Malaysian companies evaluate new production technologies, identify distribution partners and connect with regional and international buyers. The event also supports the industry’s shift toward shorter production runs, personalised packaging, energy-efficient equipment and more circular manufacturing practices.

As IPMEX enters its 16th edition, the exhibition reinforces Malaysia’s role as an ASEAN gateway for printing, packaging and visual communication technologies, while creating a platform for cross-border sourcing, technology adoption and partnerships. IPMEX Malaysia 2026 continues at MITEC until 15 August 2026.

About IPMEX Malaysia

IPMEX Malaysia is an established biennial business-to-business trade exhibition serving the printing, paper, packaging machinery, labelling, publishing and connected visual communication industries. Organised by Kaizer Exhibitions & Conferences Sdn Bhd, the exhibition has evolved over 16 editions from an industrial printing machinery show into an integrated regional platform covering digital printing, smart labels, flexible packaging, textile printing, signage and sustainable production technologies. IPMEX connects manufacturers, technology providers, printers, converters, brand owners, distributors and trade buyers through live demonstrations, business matching and cross-border networking.

Website: https://kaizer.com.my/ipmex-malaysia/

• Approximately USD 400 million project designed to produce around 62,500 cubic meters of desalinated water per day and 500,000 tons of high-purity industrial salt a year
• Advances Indonesia’s water and industrial-salt security in a single integrated facility at Manyar, Gresik, East Java
• Joint development agreement signed at Danantara’s office in Jakarta and witnessed by H.E. Rosan Roeslani, Chief Executive Officer of Danantara, and Minister of Investment of the Republic of Indonesia

JAKARTA, Indonesia and RIYADH, Saudi Arabia, Aug. 12, 2026 /PRNewswire/ — Saudi-listed Acwa (formerly ACWA Power), the world’s largest private water desalination company, a leader in the energy transition, and a first mover into green hydrogen at scale, has signed a Joint Development Agreement with PT GARAM, Indonesia’s state-owned salt enterprise, to develop the country’s first utility-scale integrated seawater desalination and industrial salt production facility.

Left to right: Mr. Abraham Mose (President Director of PT GARAM), H.E. Mr. Rosan Roeslani (CEO Danantara, Minister of Investment of the Republic of Indonesia), H.E. Mr. Faisal Abdullah Al-Amodi (Ambassador of the Kingdom of Saudi Arabia to the Republic of Indonesia), Dr. Samir J. Serhan (Group CEO of Acwa) and Mr. Tim Anderson (President Director of PT Acwa Power Indonesia)

The agreement was signed by Abraham Mose, President Director of PT GARAM, and Tim Anderson, Chief Executive Officer of PT Acwa Power Indonesia, at Danantara’s office in Jakarta and witnessed by H.E. Rosan Roeslani, Chief Executive Officer of Danantara and Minister of Investment of the Republic of Indonesia. Planned for Manyar in Gresik, East Java, and valued at approximately USD 400 million, the facility will combine a seawater reverse-osmosis (SWRO) plant with an integrated salt production line, producing around 62,500 cubic meters of desalinated water per day and approximately 500,000 tons of high-purity industrial salt a year.

Dr. Samir J. Serhan, Chief Executive Officer of Acwa, said: “Indonesia is an important growth market for Acwa, and this agreement represents another step in our commitment to supporting the country’s long-term water and industrial needs. By combining our expertise in large-scale seawater desalination with the production of high-purity industrial salt, we have an opportunity to deliver an integrated solution that strengthens water security while supporting Indonesia’s ambition to increase domestic salt production. We look forward to working closely with PT GARAM and Danantara to advance this important project.”

The project is designed on a Build-Own-Operate basis and will be developed through a project company established in Indonesia, using a limited or non-recourse project financing structure anchored in the project’s own cash flows. Indonesia currently imports more than 4 million tons of industrial salt a year, with demand expected to rise to more than 7.7 million tons by 2028. By recovering high-purity salt as a co-product of the desalination brine-management process, the Gresik facility is designed to increase domestic salt supply while providing a reliable source of desalinated water for industrial use. The project also creates the potential, subject to feasibility, to recover additional marine minerals from the same process.

Abraham Mose, President Director of PT GARAM, said: “The signing of this Joint Development Agreement marks a significant milestone for PT GARAM in building a salt industry that is more modern, efficient, and competitive. This enables Indonesia to increase salt production capacity while also building an industrial ecosystem that integrates desalination technology, industrial salt production, energy efficiency, and the potential for developing other marine minerals. Technology and knowledge transfer are central to this collaboration, and our aim is to ensure that Indonesia has world-scale production facilities alongside the workforce capable of operating and developing them sustainably.”

Tim Anderson, Chief Executive Officer of PT Acwa Power Indonesia, said: “This is a strong foundation for developing an integrated solution tailored to Indonesia’s needs. Combining desalinated water and high-purity industrial salt production within a single facility creates the potential to address two important national priorities at once. Our focus will now be on working closely with PT GARAM to progress the project responsibly and establish the foundations for its successful long-term development.”

Under the agreement, Acwa will contribute its experience in desalination project development, technology selection, technical design, financing structure, engineering, procurement, and construction, as well as long-term operations and maintenance. The collaboration also includes knowledge and technology transfer, training, and the sharing of operating protocols with personnel from PT GARAM and the project company. PT GARAM will lead site readiness and project access, permitting, and stakeholder coordination in Indonesia, and the development of markets and commercial channels for the facility’s output.

Acwa holds more than 98 GW of global power capacity, including more than 52 GW of renewable energy, and is the world’s largest private water desalination company. Its global experience in developing, financing, constructing, and operating large-scale water and power infrastructure, together with its growing presence in Indonesia, positions the company to support the country’s long-term demand for reliable and sustainable water solutions.

About Acwa

Acwa (TADAWUL: 2082) is a Saudi-listed company and the world’s largest private water desalination company, the first mover into green hydrogen, and a leader in the global energy transition. Registered and established in 2004 in Riyadh, Saudi Arabia, Acwa employs over 4,000 people and is currently present in 16 countries in the Middle East, Africa, Central Asia, and Southeast Asia. As of July 2026, Acwa’s portfolio comprises 111 assets in operation, advanced development, or under construction, representing SAR 475 billion / USD 127 billion of assets under management and the capacity to generate 98.2 GW of power (of which 52.3 GW is renewables) and manage 9.7 million m³/day of desalinated water. The energy and water capacity generated by Acwa’s assets is delivered on a bulk basis to address the needs of state utilities and industries on long-term, off-taker contracts under utility services outsourcing and public-private partnership models.

Learn more: www.acwapower.com 

CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ — Cypherpunk Technologies Inc., (Nasdaq: CYPH) (“Cypherpunk”), today reported financial results for the second quarter ended June 30, 2026.

“In the second quarter, Cypherpunk built upon the momentum established earlier this year through the disciplined execution of our Zcash digital asset treasury strategy, increasing our treasury holdings to 323,394.38 ZEC, and welcoming Dev Ojha, founder of Valar Group, as an Advisor,” said Douglas E. Onsi, President and CEO of Cypherpunk Technologies. “Our Leap Therapeutics subsidiary reached alignment with the FDA on a proposed Phase 3 trial in a DKK1-high, second-line, metastatic colorectal cancer population, with objective response rate as the primary endpoint to support accelerated approval and overall survival to support full approval in the United States and registration globally. We are conducting a strategic process to determine the best path to advance sirexatamab, whether as an independently financed spin-out company or with a partner who shares our commitment to cancer patients.”

“In an increasingly AI-driven economy, the demand for true privacy is moving from a technical preference to a civilizational necessity. Our execution in the second quarter reinforces Cypherpunk’s conviction in Zcash as a foundational monetary asset. By growing our ZEC treasury, expanding our world-class advisory team, and continuing to back core infrastructure developers like ZODL, we are systematically positioning Cypherpunk to capture the long-term value of digital privacy adoption,” said Will McEvoy, Chief Investment Officer of Cypherpunk.

Cypherpunk Highlights:

• Zcash treasury holdings increased to 323,394.38 ZEC
  • As of August 11, 2026, Cypherpunk held a total of 323,394.38 ZEC at an average purchase price of $341.83, representing approximately 1.92% of the total circulating supply of the Zcash network.
  • ZEC is a digital currency that can be transmitted over a peer-to-peer payment system. Zcash uses a cryptographic method called “zero-knowledge proofs” to allow users to engage in financial transactions while maintaining greater privacy.
• Dev Ojha Appointed as an Advisor
• • Cypherpunk appointed Dev Ojha, the founder of Valar Group, a leading development and research team focused on the Zcash Network, as an Advisor. Valar Group has taken a significant role in developing Zakura, a high-performance full node software designed for massive scalability of Zcash, and on the Ironwood shielded pool. Dev also serves as an official ZIP Editor for Zcash protocol standards. Cypherpunk’s Advisory Team also includes: Arjun Khemani, Zcash key opinion leader; Josh Swihart, CEO of ZODL; Jeff Tiller, Chief of Staff of Gemini; and Zooko Wilcox, Founder of Zcash and Chief Product Officer at Shielded Labs.

Leap Therapeutics Subsidiary Highlights:

• Publication of randomized Phase 2 DeFianCe study in Clinical Cancer Research
  • Leap Therapeutics announced the publication of results from the randomized Phase 2 DeFianCe (NCT05480306) study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in Clinical Cancer Research. The publication, “Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial,” reported the complete efficacy, safety, and biomarker analyses from the study and details the statistical basis for the DKK1 biomarker finding.
  • The peer-reviewed analyses establish that, while the prespecified primary endpoint was not met in the intent-to-treat population, the benefit of sirexatamab increases as a patient’s baseline plasma DKK1 level rises — a relationship confirmed by independent statistical approaches and reinforced by the observation that high DKK1 predicts poorer outcomes on standard of care alone. Together, these findings define DKK1-high metastatic colorectal cancer (mCRC) as a biologically distinct population with high unmet need.
• Reached FDA alignment on registrational Phase 3 trial in DKK1-high colorectal cancer
  • Leap Therapeutics held a Type C meeting with the FDA to discuss the DeFianCe results and proposed registrational path for sirexatamab in DKK1-high, second-line mCRC. Leap presented its proposed Phase 3 trial design, and the FDA provided feedback supporting key elements of that design, including the use of a DKK1 biomarker-selected patient population and a dual-endpoint structure intended to support both accelerated and full approval.
  • Leap Therapeutics reached alignment with the FDA on a randomized, controlled Phase 3 trial evaluating sirexatamab in combination with investigator’s-choice fluoropyrimidine-based chemotherapy (FOLFIRI or mFOLFOX6) plus bevacizumab, compared with chemotherapy and bevacizumab alone. Approximately 270 patients with mCRC whose disease has progressed following one prior line of systemic therapy prospectively identified as DKK1-high using a baseline plasma DKK1 assay cut point are expected to be enrolled and randomized 1:1. Potential accelerated approval in the United States could be determined by objective response rate (ORR) in an initial group of approximately 160 patients, and overall survival (OS) will be evaluated in the full study population intended to support a filing for full approval in the United States and to support registration in markets outside the United States.
  • A blood-based companion diagnostic would be developed in parallel to identify DKK1-high patients in routine clinical practice.
• Sirexatamab received Fast Track designation from FDA
  • In May 2026, the FDA granted Fast Track designation to sirexatamab in combination with fluoropyrimidine plus oxaliplatin- or irinotecan-based chemotherapy and bevacizumab, for the treatment of patients with DKK1-high mCRC whose disease has progressed following one prior systemic therapy.
  • The Fast Track program is intended to facilitate the development and expedite the review of drug candidates and vaccines that treat serious conditions and fill an unmet medical need. Programs with Fast Track designation may benefit from frequent communication with the FDA, in addition to a rolling submission of the marketing application.
• Business update
  • Leap Therapeutics has initiated a strategic process to identify the best path forward for sirexatamab and to secure the resources required to advance the program into Phase 3 development. The process is expected to consider a range of alternatives, which may include financing the program as an independent entity, or a strategic transaction with a pharmaceutical or biotechnology company, including a partnership, license, collaboration, sale, or other business combination.
  • There can be no assurance that the strategic process will result in any transaction or financing, or that any transaction or financing that is completed will be on terms favorable to the Company or its stockholders. The Company has not set a timetable for the conclusion of the process and does not intend to disclose developments unless and until it determines that further disclosure is appropriate or required.

Selected Second Quarter 2026 Financial Results

Net income was $39.4 million, or $0.18 per diluted share, for the second quarter of 2026, compared to a net loss of $16.6 million for the second quarter of 2025. The change was primarily due to a $46.0 million unrealized gain on the fair value of the Company’s ZEC treasury holdings during the second quarter of 2026, which are marked to market at the end of each period. During the second quarter of 2026, the price of ZEC increased from $243.35 to $400.09.

Research and development expenses were $0.2 million for the three months ended June 30, 2026, compared to $10.5 million for the same period in 2025. The decrease was primarily due to a decrease in clinical trial and manufacturing expenses due to the completion of the clinical trials, together with a decrease in payroll and related expenses associated with the 2025 reduction in force.

General and administrative expenses were $4.5 million for the three months ended June 30, 2026, compared to $1.8 million for the same period in 2025. The increase of $2.7 million for the three months ended June 30, 2026 was primarily due to a $1.7 million increase in stock-based compensation related to restricted stock units granted to general and administrative employees and directors in the fourth quarter of 2025, a $0.8 million increase in payroll and related expenses, and a $0.2 million increase in professional fees.

During the three months ended June 30, 2026, the Company recorded a $46.0 million unrealized gain on the change in fair value of the Company’s ZEC treasury holdings as the price of ZEC increased during the second quarter of 2026 from $243.35 to $400.09.

Cash and cash equivalents totaled $7.6 million on June 30, 2026, and ZEC treasury holdings, categorized as digital asset receivable, totaled $129.4 million based on the ZEC price of $400.09 on June 30, 2026.

About Cypherpunk

Cypherpunk Technologies is a privacy technology company. The Company’s mission is to advance technologies that guarantee privacy for humans on the internet. Cypherpunk pursues this mission through two primary strategies: accumulating Zcash (ZEC); and investing in, acquiring, and building technologies that push the frontier of privacy forward. Additionally, through its subsidiary Leap Therapeutics, the Company is developing novel therapies for patients with cancer, continuing the development of sirexatamab and FL-501. For more information about the Company, visit our websites at http://www.cypherpunk.com and http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov.

FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. Forward-looking statements address various matters including statements relating to the value of the Company’s ZEC holdings, the investment in Zcash Open Development Labs (“ZODL”), or digital assets held or to be held by the Company, the expected future market, price, and liquidity of ZEC or other digital assets the Company acquires, the macro and political conditions surrounding Zcash or digital assets, the Company’s plan for value creation and strategic advantages, market size and growth opportunities, regulatory conditions, competitive position and the interest of other corporations in similar business strategies, technological and market trends, and future financial condition and performance. Risks and uncertainties of the digital asset treasury strategy include, among others: (a) risks relating to the Company’s operations and business, including the highly volatile nature of the price of ZEC; (b) the risk that material changes in the price of ZEC, such as decreases in price, will result in significant changes to the Company’s financial statements, such as unrealized losses on fair value of ZEC holdings and net loss; (c) the risk that the price of the Company’s common stock may be highly correlated to the price of ZEC; (d) the risk that the Company will fail to realize the anticipated benefits of the ZEC digital asset treasury strategy or the investment in ZODL; (e) risks related to the custody of our ZEC and our reliance on Gemini Space Station and its affiliates for trading and custody services; (f) changes in business, market, financial, political and regulatory conditions; (g) risks related to increased competition in the industries in which the Company does and will operate; (h) risks relating to significant legal, commercial, regulatory and technical uncertainty regarding digital assets generally; (i) risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and (j) the Company’s ability to comply with the continued listing requirements of the Nasdaq Capital Market.

With respect to our biotechnology operations, important factors that could cause actual results to differ materially from our plans, estimates or expectations could include, but are not limited to: (i) the DeFianCe study did not meet its prespecified primary endpoint of progression-free survival in the intent-to-treat population; (ii) the DKK1 biomarker subgroup and interaction analyses were exploratory, were based on a limited number of patients, were not adjusted for multiplicity, and may not be replicated in a prospective clinical trial; (iii) the impact of imbalances between treatment arms in the DKK1 subgroups; (iv) the risk that alignment with the FDA on trial design does not constitute agreement that any trial will succeed or that any marketing application will be accepted or approved, and the FDA may change its position at any time; (v) accelerated approval, if pursued, requires that the surrogate endpoint be reasonably likely to predict clinical benefit and is subject to confirmatory trial requirements and possible withdrawal if such requirements are not satisfied; (vi) the Company’s ability to initiate or complete the Phase 3 trial on the anticipated timeline or at all; (vii) the Company’s ability to obtain additional capital to advance sirexatamab on acceptable terms or at all; (viii) that risk that the strategic process may not result in any transaction or financing, may be terminated at any time, and any resulting transaction may not be on terms favorable to the Company or its stockholders; (ix) the Company’s ability to develop and validate a companion diagnostic; (x) the success of competing therapies; (xi) the Company’s ability to secure manufacturing capacity for sirexatamab; and (xii) the Company’s ability to maintain and protect its intellectual property rights.

New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. The Company may not actually achieve the forecasts disclosed in such forward-looking statements, and you should not place undue reliance on such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the SEC, or as may be included in other reports or information we file with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in its subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither the Company, nor any of its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

CONTACT:
Douglas E. Onsi
President & Chief Executive Officer
Cypherpunk Technologies Inc.
617-714-0360

For Investors:
Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
leap@argotpartners.com

For Media:
Jacqueline Ortiz Ramsay
It Factor Strategies
954-294-3249
jacqueline@itfactorstrategies.com

A pocket-sized AI workmate that turns everyday conversations into follow-up emails, presentation drafts, and finished action lists, and makes AI easier to use for everyone.

SAN JOSE, Calif., Aug. 12, 2026 /PRNewswire/ — AI has become increasingly powerful, helping people generate content, answer questions, and process information faster than ever. Yet for many users, putting AI into daily workflows still feels complicated. Learning prompts, switching between tools, and building AI workflows can create barriers before users ever experience the value AI can bring.

Comu Action Pro is designed to change that.

As a pocket-sized AI workmate, Comu Action Pro helps users capture conversations, understand what matters, and turn discussions into practical outcomes, from follow-up emails and presentation drafts to action lists and organized insights. Instead of asking users to learn how to work with AI, Comu is built around a simpler idea:

AI should adapt to people, not the other way around.

Beyond Notes. Into Action.

Traditional AI voice recorders have made capturing conversations easier. But recording is only the beginning. The real challenge starts after the conversation ends.

A meeting creates decisions. An interview creates insights. A customer conversation creates opportunities. But turning those moments into emails, presentations, tasks, and next steps still requires time and manual effort.

That is the work that often fills the 30 minutes after a meeting ends: writing follow-up emails, organizing action items, and turning notes into presentations.

Comu Action Pro goes beyond transcription and summaries by using AI to transform conversations into practical work outputs. Instead of leaving users with another transcript to review, Comu helps turn conversations into actions:

• Follow-up Emails
  Transform conversations into structured follow-up drafts, helping users quickly communicate decisions and next steps.
• Action Items & Task Lists
  Identify key decisions, responsibilities, and next steps so important details are captured and easier to act on.
• Presentation Drafts
  Turn discussions and ideas into organized presentation outlines, reducing the time spent structuring information.
• Structured Notes & Summaries
  Create clear summaries and organized insights that make conversations easier to review, share, and apply.

By moving beyond recording and note-taking, Comu Action Pro helps users capture conversations, understand what matters, and create meaningful outputs from every discussion.

Capture Every Conversation, Wherever Work Happens

Important ideas rarely happen in perfect environments. They happen during meetings, customer conversations, interviews, networking events, and moments of inspiration.

Comu Action Pro is built with dedicated hardware designed specifically for capturing real-world conversations, so users can focus on the discussion instead of the technology:

• 6-microphone adaptive array for improved voice capture in group settings
• AI-powered noise reduction to handle complex, noisy environments
• Up to 70 hours of recording capability for long meetings, full-day interviews, and travel

Understand What Matters, Not Just What Was Said

Recording words is easy. Understanding meaning is where AI creates real value.

Comu Action Pro uses AI to identify the important information within a conversation, helping users recognize key decisions, important topics, responsibilities, and next steps. Rather than leaving users with another transcript to review, Comu transforms conversations into structured insight.

Make Every Conversation More Productive

The value of AI is not just saving information. It’s helping people complete work.

Comu Action Pro converts conversations into practical outputs, including follow-up email drafts, presentation outlines, action lists, and organized summaries. It cuts out the repetitive work that usually follows a meeting or conversation, so users spend less time processing information and more time moving ideas forward.

Designed for Everyone, Not Just AI Experts

Many AI tools require users to understand prompts, learn workflows, or connect multiple applications before they become useful. Comu takes a different approach, and it starts with a single dedicated AI button built into the device.

No need to learn complicated workflows or master prompt writing. Users simply press the button and speak naturally, just as they would with a colleague. Comu helps transform those conversations into actionable tasks, organized ideas, follow-up emails, and presentation drafts. That one design choice is what actually lowers the barrier to using AI. It removes the steps that usually stand between having an idea and doing something with it, so people don’t need to learn how AI works before they can benefit from it.

Whether someone is an AI expert or just beginning to explore it, Comu Action Pro makes advanced AI capabilities easier to access.

Why Dedicated Hardware Still Matters

With smartphones already capable of recording audio, why create another device?

Because capturing important conversations requires more than a recording function. A phone’s recording is easily interrupted by calls and notifications, and its microphone typically hears whoever happens to be closest to it, not necessarily the person speaking. Dedicated hardware removes that friction, offering faster access when important moments happen, a distraction-free experience, and audio performance built specifically for real conversations rather than borrowed from a general-purpose device.

Comu Action Pro isn’t designed to replace your phone. It’s designed to do one thing better: turning conversations into outcomes, whether that’s a team meeting, an interview, a customer discussion, or a creative brainstorm. With support for 113+ languages and long-lasting battery performance, it’s built to keep up with individuals and teams across a wide range of real-world conversations.

Built Around Business-Grade Data Protection

Many of the conversations Comu Action Pro captures involve sensitive information: client details, internal decisions, unreleased plans. Comu’s security program is built around business data protection requirements, with support for standards and frameworks including GDPR, HIPAA, and SOC II.

For teams handling confidential conversations on a daily basis, that protection isn’t a footnote. It’s part of what makes the device usable in real business settings, not just casual note-taking.

Limited-Time Launch Offer

From August 12 through September 13, 2026, customers can purchase Comu Action Pro for $169.99 with promo code COMULAUNCH20 at checkout.

• Amazon: https://amzn.to/4wS6YKN
• Comu Official Website: https://bit.ly/4xvO64b

Offer availability, promo code eligibility and inventory may vary by sales channel. Terms and conditions apply.

About Comu

Comu is building a new generation of AI productivity tools that help people move from capturing information to acting on it.

Originally developed as Comulytic, Comu has evolved beyond AI note-taking into an AI workmate that combines dedicated hardware with intelligent workflows. Comu believes AI should not add complexity to everyday work. It should make work simpler, more natural, and more productive.

For more information, please visit: https://store.comu.com/